Identification of Novel 4-Oxo-4H-chromen-Hydroxamic Acid Derivative Targeting Selected HDAC Isoforms

Rosaline Ashraf, Mai Adel, Rabah Serya, Khaled Abouzid
{"title":"Identification of Novel 4-Oxo-4H-chromen-Hydroxamic Acid Derivative Targeting Selected HDAC Isoforms","authors":"Rosaline Ashraf, Mai Adel, Rabah Serya, Khaled Abouzid","doi":"10.21608/aps.2023.226661.1128","DOIUrl":null,"url":null,"abstract":"Histone deacetylase inhibitors (HDACIs) represent a well-known class of compounds that exhibit potential therapeutic efficacy in a variety of diseases, particularly cancer and neurodegenerative disorders. This article discusses the development of compound 6 as a new HDAC inhibitor. It was designed based on the structure-activity relationship (SAR) of the previously reported HDAC inhibitors and the molecular modeling studies. Compound 6 was synthesized, and its structure was verified using different spectroscopic methods. It was biologically evaluated to assess its inhibitory activity against different HDAC isoforms, including HDAC1, 6, and 8. The results showed moderate inhibition against HDAC 1 and HDAC 8 over HDAC 6. It was also evaluated for its antineoplastic activity against the NCI 60 cancer cell line panel. The results revealed inhibitory activity against both the UO-31 renal cancer cell line and the BT-549 breast cancer cell line. Moreover, the Molecular modeling studies revealed a favorable binding affinity for the HDAC8 active site. These results suggest that compound 6 can be considered a promising candidate for the development of new selective class I HDACIs in the future.","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Pharmaceutical Sciences Ain Shams University","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/aps.2023.226661.1128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Histone deacetylase inhibitors (HDACIs) represent a well-known class of compounds that exhibit potential therapeutic efficacy in a variety of diseases, particularly cancer and neurodegenerative disorders. This article discusses the development of compound 6 as a new HDAC inhibitor. It was designed based on the structure-activity relationship (SAR) of the previously reported HDAC inhibitors and the molecular modeling studies. Compound 6 was synthesized, and its structure was verified using different spectroscopic methods. It was biologically evaluated to assess its inhibitory activity against different HDAC isoforms, including HDAC1, 6, and 8. The results showed moderate inhibition against HDAC 1 and HDAC 8 over HDAC 6. It was also evaluated for its antineoplastic activity against the NCI 60 cancer cell line panel. The results revealed inhibitory activity against both the UO-31 renal cancer cell line and the BT-549 breast cancer cell line. Moreover, the Molecular modeling studies revealed a favorable binding affinity for the HDAC8 active site. These results suggest that compound 6 can be considered a promising candidate for the development of new selective class I HDACIs in the future.
靶向HDAC亚型的新型4-氧- 4h -铬-羟肟酸衍生物的鉴定
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
15
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信